LUGPA Annual Meeting | Conference

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

November 4th 2016

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Koo on Degarelix for the Treatment of Prostate Cancer

November 24th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association, discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Dr. Koo Discusses Focal Therapy for Prostate Cancer

November 10th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Dr. Kirsh Discusses the Future of Treating Prostate Cancer

November 10th 2015

Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Dr. Buffington on Degarelix and Appropriate Patients

November 7th 2015

Philip J. Buffington, MD, chief medical officer at The Urology Group, discusses administering degarelix (Firmagon) and determining which patients to treat with the hormonal therapy.buffington-thumb.jpg

Physician Dispensing of Abiraterone and Enzalutamide for mCRPC Gains Appeal

November 7th 2015

With the emergence of the novel treatments abiraterone acetate (Zytiga) and enzalutamide (Xtandi), urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer patients.

Physicians on the Offense: Get Organized to Thrive in This Payment Arena

November 7th 2015

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Dr. Kapoor on LUGPA's Legislative Advocacy

November 6th 2015

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

Deliver Androgen Blockade at Prostate Cancer Cells to Achieve Castrate Levels

November 6th 2015

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

Dr. Concepcion Discusses Healthcare's Transition Away From Fee-For-Service

November 6th 2015

Raoul S. Concepcion, MD, FACS, director of Advanced Therapeutics at Urology Associates, PC, discusses healthcare's movement away from fee-for-service reimbursements.

Novel Combinations Hold Promise in Treatment-Resistant mCRPC

November 6th 2015

Thomas E. Keane, MD, ChB, discussed combination approaches in treatment-resistant mCRPC at the 2015 LUGPA Annual Meeting.

Crawford Questions ADT Standards, Approaches in Prostate Cancer

November 6th 2015

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.

Dr. Goldfischer on Integrated Medical Groups

November 6th 2015

Evan R. Goldfischer, MD, MBA, FACS, director of the Research Department at Premier Medical Group of the Hudson Valley, discusses the benefits of integrated medical groups.

LUGPA Meeting Focuses on Business and Clinical Challenges

November 4th 2015

Independent urology practices are at a crossroads as they face substantial Medicare payment change, shifts in physician employment and autonomy, and cutting edge developments in clinical care.

Recently Approved Therapies Bring New Understanding in Management of Prostate Cancer

November 2nd 2012

After many years of treating patients with advanced prostate cancer the same way, a host of new drug approvals has not only changed the way urologists manage prostate cancer but their understanding of the disease as well.

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

November 2nd 2012

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Meeting Addresses Challenges Facing Urology Groups in Cancer Care

November 1st 2012

The 2012 LUGPA Annual Meeting is expected to gather more than 100 urology groups to discuss administrative, technological, regulatory, and medical challenges facing practices.

Dr. Freedland on Treating Early-Stage Prostate Cancer

October 31st 2012

Stephen J. Freedland, MD, from Duke University School of Medicine, discusses the complications faced when treating men with early-stage prostate cancer.